Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose Aspirin

New England Journal of Medicine

Volumn 301, Issue 11, 1979, Pages 577-579

  Harter, Herschel R ^a   Burch, John W ^a   Majerus, Philip W ^a   Stanford, Nancy ^a   Delmez, James A ^a   Anderson, Charles B ^a   Weerts, Carol A ^a  

^a University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

CLINICAL TRIAL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREVENTION; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL; THERAPY; THROMBOCYTE; THROMBOSIS;

EID: 0018727443     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197909133011103     Document Type: Article

References (19)

1. Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial. N Engl J Med 298: 289–295, 1978
2. The Coronary Drug Project Research Group: Aspirin in coronary heart disease. J Chronic Dis 29: 625–642, 1976
3. Elwood PC, Cochrane AL, Burr ML, et al: A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1: 436–440, 1974
4. Moncada S, Vane JR: The discovery of prostacyclin — a fresh insight into arachiconic acid metabolism, Biochemical Aspects of Prostaglandins and Thromboxanes. Edited by N Kharasch, J Fried. New York, Academic Press, 1977, pp 155–177
5. Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72: 3073–3076, 1975
6. Burch JW, Stanford N, Majerus PW: Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61: 314–319, 1978
7. Burch JW, Baenziger NL, Stanford N, et al: Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci USA 75: 5181–5184, 1978
8. Baenziger NL, Becherer PR, Majerus PW: Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells, and skin fibroblasts. Cell 16: 967–974, 1979
9. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particular fraction protein. J Clin Invest 56: 624–632, 1975
10. Kaegi A, Pineo GF, Shimizu A, et al: Arteriovenous-shunt thrombosis: prevention by sulfinpyrazone. N Engl J Med 290: 304–306, 1974
11. Wing AJ, Curtis JR, De Wardener HE: Reduction of clotting in Scribner shunts by long-term anticoagulation. Br Med J 3: 143–145, 1967
12. Kaegi A, Pineo GF, Shimizu A, et al: The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 52: 497–499, 1975
13. Harris WH, Salzman EW, Athanasoulis CA, et al: Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 297: 1246–1249, 1977
14. Quinton WE, Dillard DH, Cole JJ, et al: Eight months’ experience with Silastic-Teflon bypass cannulas. Trans Am Soc Artif Intern Organs 8: 236–245, 1962
15. Farooki MS, Gergely NF, McAninch LN: External arteriovenous shunts for intermittent long-term hemodialysis: five years’ experience. Can Med Assoc J 103: 1371–1374, 1970
16. Cohen BH, Chinitz JL, Soll KH: Radiological contrast study of arteriovenous dialysis cannulae. Radiology 94: 603–606, 1970
17. De Palma JR, Golding A, Maxwell MH: Evaluation of A-V cannula malfunction and clotting using shunt-angiography. Trans Am Soc Artif Intern Organs 15: 278–284, 1969
18. Glashan RW, Walker F: A histological examination of veins used in artificial arteriovenous (‘Quinton/Scribner’) shunts. Br J Surg 55: 189–193, 1968
19. O'Grady J, Moncada S: Aspirin: a paradoxical effect on bleeding-time. Lancet 2: 780, 1978